With over 100 years of multiproduct manufacturing and developing in oncology therapies and vaccines, our Pearl River site offers development, designed to handle cytotoxic compounds from drug substance intermediate to sterile drug product manufacturing. For over 22 years, this facility has produced commercial and clinical antibody drug conjugates (ADCs). Pearl River has a range of specialist capabilities in producing nanoparticle/microparticle conjugates and other cytotoxic and highly potent compounds in accordance with current good manufacturing practices. Operating staff have extensive antibody drug conjugate manufacturing experience spanning project management, technical transfer, qualification, and cGMP compliance.
Explore more from our global development network
